The Mexican Patent Office has granted Bio3 Research S.r.l. a patent for the use of oral cysteine (Biocysan™) in hemodialysed patients (End Stage Renal Disease – ESRD). For more details please refer to the herewith pdf file.
June 12, 2008:
Bio3 Research S.r.l. (Milano – Italy), is pleased to announce the official opening of a Californian subsidiary, located in Hayward.
The opening of Bio3 Research Inc., will enable the company to expand its activities in one of the most dynamic cluster, Silicon Valley, synonym of technology and innovation, which represents the ideal place for biomedical firms specialized in the areas of R&D in the life sciences and biopharmaceuticals, with the common purpose of improving the quality of human health and life.
Bio3 Research with the presence of a Californian subsidiary will also strengthen its strategic collaboration with two Californian based companies, Protelix Inc. and SynGen Inc., for the development of SiRNA HMGB1 specific and Mimic antibodies against HMGB1 in cardiovascular disorder related to HMGB1.
Other alliances will be worked out to develop HMGB1 in connective tissues regeneration.
A presence in the USA will also enable Bio3 Research to develop its proprietary compound Biocysan (cysteine) in the prevention of severe anemia in hemodialysed patients.
November 26, 2007:
The European Patent Office has granted Bio3 Research S.r.l. a patent for the use of oral cysteine (Biocysan™) in hemodialysed patients - End Stage Renal Disease. For more details please refer to the herewith pdf file.
The European Patent Office has granted Bio3 Research S.r.l. a patent for the use of oral cysteine (Biocysan™) in hemodialysed patients - End Stage Renal Disease. For more details please refer to the herewith pdf file.
May 30, 2007:
The British Medicines and Healthcare products Regulatory Agency (MHRA) has authorizedCreabilis Therapeutics, Italy,to carry out Phase I Clinical Trial in the UK for CT327 (Pegylated K252A) for the topical treatment of Psoriasis .The proprietarycompound is under development at Creabilis Therapeutics S.p.A laboratories (Italy). Creabilis Therapeutics has granted Bio3 Research s.r.l exclusive worldwide business development rights for CT327 licensing out.
April 16, 2007:
Bio3 Research S.r.l. (Milan – Italy) and Daxley Group (Montevideo – Uruguay) today announced a Phase III trial will start in Mexico in May 2007 to evaluate the supportive treatment of Biocysan™, oral cysteine, in hemodialysed patients (End Stage Renal Disease).
March 15, 2007:
Bio3 Research S.r.l. has been granted by the Australian Patent Office a patent in the field of cardiovascular diseases related to HMGB1 over-expression and for the use of HMGB1 protein in connective tissue regeneration. For more details please refer to the herewith pdf file
March 28, 2006:
Bio3 Research has licensed-out Biocysan to the Latin American pharmaceutical group Daxley for Latin America and Mexico. For more details please refer to the herewith pdf file.
November 30, 2005:
Bio3 Research and Creabilis Therapeutics sign research agreements with Cephalon, Inc. Research will focus on potential new treatments for psoriasis and restenosis. For more details please refer to the herewith pdf file.
March 17, 2005:
The patent "HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases" has been granted in Italy.
January 26, 2005: Bio3 Research PCT filing in the field of Restenosis (Proliferation Patent)
A patent application has been filed under the PCT entitled "HMGB1 Antagonists and Inhibitors to prevent Endothelial and SMC proliferation".
January 21, 2005: Bio3 Research PCT filing in the field of Atherosclerosis
Bio3 Research has filed a patent application, in co-ownership with Prof. Marco Bianchi, Group Leader, Chromatin Dynamics Unit, San Raffaele Scientific Institute (Milan - Italy), in Italy under the title "HMGB1 protein inhibitors and/or antagonists inhibiting the pathogenesis and progression of the Atherosclerotic disease".
December 17, 2004: Bio3 Research PCT filing in the field of End-Stage Renal Disease.
Bio3 Research has filed a patent application under the PCT claiming the use of a specific amino acid to decrease anemia in end-stage renal disease (ESRD) patients.
August 2, 2004: Bio3 Research - Creabilis Therapeutics Licensing agreement in the field of Vascular Disorders and Restenosis
Bio3 Research has entered into a Cross-License agreement with Creabilis Therapeutics, an Italian drug discovery and development company by granting Creabilis Therapeutics exclusive rights to develop and exploit Bio3 Research four way DNA as HMGB1 antagonist in the cardiovascular area. In turn Bio3 Research has obtained from Creabilis Therapeutics, an exclusive worldwide license of certain products, such as short duplex bent DNA, bent PNA, DNA/PNA hybrids, DNA/PNA chimeras (coded CT400 series), under development by Creabilis Therapeutics in the cardiovascular field under Creabilis Therapeutics patent "Therapeutic agents for the treatment of HMGB1-related pathologies".
August 2, 2004: Bio3 Research - Creabilis Therapeutics joint patent filing in the field of Restenosis (CT301/R)
Bio3 Research and Creabilis Therapeutics have jointly filed a patent application for the use of the compound coded CT301/R in restenosis. CT301/R, a small liposoluble molecule, has a potent indirect inhibiting effect on HMGB1, resulting in anti-proliferative and anti-migration effects on BASMC and BAEC cells. Bio3 Research has worldwide exclusive licensing-out rights.
August 2, Bio3 Research - Creabilis Therapeutics agreement for the promotion of a compound (coded CT301/P) under development at Creabilis Therapeutics for the topical treatment of Psoriasis
Bio3 Research and Creabilis Therapeutics have entered into a strategic alliance for the promotion and licensing-out of CT301/P, a compound under development for the topical treatment of psoriasis. Under this agreement, Bio3 Research will assist Creabilis Therapeutics in strategic marketing, business development and licensing-out activities.
May 14, 2004: Worldwide license of the polymer free Drug Eluting Stent Endostent from the Swiss company Endosense.
Endosense, a Swiss medical device company engaged in the development of devices for the treatment of vascular disorders, has granted Bio3 Research a worldwide semi-exclusive license for their proprietary polymer free drug-eluting stent Endostent.
February 3, 2004: Bio3 Research patent application filing in the field of Restenosis
Bio3 Research has filed an Italian priority application for a patent under the title "HMGB1 Antagonists and Inhibitors to prevent Endothelial and SMC proliferation". This patent is the result of a collaboration established with Prof. Marco Bianchi, Group Leader, Chromatin Dynamics Unit, San Raffaele Scientific Institute (Milan - Italy), internationally renowned in the field of HMGB1.
September 15, 2003: Bio3 Research Nationalization Phases undertaken for the PCT WO 02/074337 in the field of Restenosis
Bio3 Research has undertaken the nationalization phase in USA, EU, JP, Canada, Australia, China for the patent application "HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases".
July 22, 2003: Termination of the agreement between Bio3 Research and Lay Line Genomics (LLG).
Bio3 Research announces the termination of its agreement with Lay Line Genomics. Under the collaboration established in the year 2001 Bio3 Research helped LLG to enter into service and non-exclusive license contracts with leading pharmaceutical companies for the use of LLGs transgenic anti-NGF mouse AD11.
September 26, 2002: Bio3 Research PCT filing in the field of Restenosis
Bio3 Research has filed a patent application under the PCT entitled "HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases".
October 28, 2001: Bio3 Research has entered into an agreement with Lay Line Genomics.
Under the agreement Bio3 Research will assist Lay Line Genomics (LLG), an Italian company engaged in the development of new drugs and innovative therapies for Alzheimer's and other neurological diseases, in licensing out the use of LLG's anti-NGF mouse AD11.
Bio3 News...
Bio3 Research S.r.l. (Milano – Italy), is pleased to announce the official
opening of a Californian subsidiary, located in Hayward…
